For the roughly half-million Americans on hemodialysis, the lifeline is not the machine in the clinic. It is the surgically created vascular access in the arm, an arteriovenous fistula or graft, that lets blood cycle out and back three times a week. When that access narrows or clots, treatment stops. Patients land in the emergency room, often needing a catheter placed urgently, and a meaningful share never recover full function of the original site. Auvi Labs, a Chicago healthtech company founded in 2024, is building a wearable ultrasound patch called Beacon that patients wear for ten minutes a day at home to catch those failures before they become emergencies [Auvi Labs].
The product, as the company describes it, is a non-invasive wearable designed for the early detection of dialysis access failure [Auvi Labs]. According to a Delta: HealthTech Innovators podcast appearance, Beacon is a patch-form ultrasound device that measures blood flow through the access site in a brief daily session [Delta: HealthTech Innovators Podcast]. The pitch is straightforward: shift surveillance from intermittent in-clinic physical exams and periodic imaging to a continuous, patient-administered signal that can flag a stenosis or thrombosis days or weeks before it shuts down treatment.
The bet
Auvi Labs is selling a hardware-plus-software combination into a clinical workflow that, today, has very few good answers. The company pairs the wearable with a monitoring platform intended to surface access issues to the care team [Crunchbase]. Founder and CEO Rishab Veldur, who has a software engineering background and is affiliated with the University of Illinois, has represented the company in pitch competitions, including a first-place finish for the wearable ultrasound device and a second-place pitch presentation finish [Yasmeen Butt LinkedIn] [Paul Magelli LinkedIn]. The company's about page lists clinical input from Kevin Volkema, DO, MBA, among advisors [Auvi Labs].
The wedge here is the patient population's predictability. People on maintenance hemodialysis are already enrolled, already monitored, already attached to a nephrology practice or a dialysis chain such as Fresenius or DaVita. They are a defined cohort with a recurring clinical need, which makes them well suited to a daily-use device with a reimbursement story tied to avoided hospitalizations and preserved access.
The standard of care today
Current surveillance for arteriovenous access relies on a mix of physical examination at each dialysis session (look, listen, feel for the bruit and thrill), monitoring of dynamic venous pressures and access flow during treatment, and referral for duplex ultrasound or angiography when something seems off. KDOQI guidelines have moved over the past decade away from routine surveillance imaging toward clinical monitoring, partly because earlier surveillance programs did not consistently reduce thrombosis rates. The result is a system that often catches access failure late, after flow has already dropped enough to compromise a treatment session, with a missed-fistula salvage frequently meaning a tunneled catheter and elevated infection risk. Anything that reliably moves detection earlier, and does so without adding clinic burden, has a real clinical case to make.
Why it could matter
Dialysis is one of the most expensive chronic-care categories in American medicine, and access complications are a disproportionate driver of that spend. Medicare's ESRD program structure, including bundled payments and the ETC model's push toward home modalities, gives providers a direct financial incentive to keep patients out of the hospital and on their existing access. A wearable that credibly extends the life of a fistula, or that prevents even a fraction of urgent catheter placements, fits cleanly into that incentive structure. The home-dialysis tailwind matters too: as more patients dialyze outside a clinic, the in-person eyes-and-hands surveillance that the field has relied on becomes harder to deliver, and a patient-worn sensor becomes more valuable.
Auvi Labs has raised approximately $101,000 in seed funding to date [Leads on Trees]. That is a small figure relative to what a Class II wearable medical device program will eventually require, but it is consistent with a 2024-vintage company still in early prototyping and pre-submission work.
Seed funding disclosed | 0.101 | $M
The competitive picture
Auvi Labs is not the first team to see this opportunity. Alio, a more established company, has developed a wearable patch (SmartPatch) that monitors hemoglobin, heart rate, and other parameters in dialysis patients and received FDA clearances for elements of its platform. Alio's existence is both validation that payers and providers will engage with wearable monitoring in this population, and a reminder that Auvi will need to articulate clearly what its ultrasound-based flow measurement does that optical and electrochemical sensing does not. The bull case for Beacon rests on a specific clinical claim: direct measurement of access blood flow is a more proximate signal of impending access failure than systemic physiologic markers, and a brief daily ultrasound reading should detect stenosis earlier than downstream indicators. That claim will need peer-reviewed data to stick.
The honest counterfactual
The central risk is regulatory and evidentiary. A wearable ultrasound patch making a clinical detection claim in a high-acuity population is almost certainly a Class II device requiring FDA 510(k) clearance, and the meaningful version of the claim, that Beacon detects access failure earlier than standard monitoring and that earlier detection improves outcomes, will require a prospective clinical study. Bears will note that the company has not yet disclosed an FDA submission, a pivotal study design, or peer-reviewed validation of the underlying flow measurement. The bull answer, supported by the public record, is that Auvi is appropriately staged for a company of its age: prototype in hand, clinical advisor engaged, competition wins suggesting the device works well enough to demo, and a seed round sized to fund the next technical milestones rather than a pivotal trial it is not yet ready to run.
What to watch
The next twelve months should bring three readable signals. First, a priced seed extension or a proper seed round in the low single-digit millions, which is what this kind of hardware program typically needs to reach a 510(k) submission. Second, a named clinical partner, likely an academic nephrology program or a mid-sized dialysis provider, willing to host a feasibility study. Third, any peer-reviewed or conference-presented data on Beacon's flow measurement accuracy against duplex ultrasound as a reference standard. Until at least one of those lands, Auvi remains a promising early bet on an underserved patient group rather than a proven clinical tool. The patient population, however, is not waiting, and the case for trying is strong.
Pulse Raman, Health and Bio Correspondent